|Bid||16.96 x 1100|
|Ask||19.00 x 1100|
|Day's range||16.96 - 17.95|
|52-week range||12.93 - 25.70|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||34.94|
|Earnings date||25 Jun 2020 - 29 Jun 2020|
|Forward dividend & yield||1.04 (6.00%)|
|Ex-dividend date||08 Apr 2020|
|1y target est||20.73|
Patterson Companies, Inc. (Nasdaq: PDCO) today provided an update on the impact of COVID-19 on the Company’s operations and withdrew its fiscal year 2020 financial guidance.
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Board of Directors of Patterson Companies, Inc. (Nasdaq: PDCO) today declared a quarterly cash dividend of $0.26 per share. The dividend will be payable on, or about, April 24, 2020, to shareholders of record as of the close of business on April 10, 2020.
Patterson Companies (PDCO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Patterson Companies (PDCO) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Patterson Cos. (PDCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Patterson Companies' (PDCO) fiscal third-quarter results benefit from higher revenues and solid show by Dental as well as Animal Health segments.
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 27.03% and 2.75%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?
Patterson Companies, Inc. (PDCO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.